Eflornithine/sulindac

Drug Profile

Eflornithine/sulindac

Alternative Names: CPP-1X/sul; CPP-1X/sulindac; CPP1-x/sulindac; Sulindac/CPP-1X; Sulindac/eflornithine; TP 09

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis; University of Arizona
  • Developer Cancer Prevention Pharmaceuticals; Genzyme Corporation; National Cancer Institute (USA); World Health Organization
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Indenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Trypanosomiasis
  • Phase III Colorectal cancer; Familial adenomatous polyposis
  • Discontinued Basal cell cancer; Bladder cancer; Prostate cancer; Sporadic adenomas; Squamous cell cancer

Most Recent Events

  • 18 Sep 2017 Eflornithine/sulindac receives Fast Track designation for Familial adenomatous polyposis [PO,Tablet] (Combination therapy) in USA
  • 15 Dec 2016 Biomarkers information updated
  • 04 Apr 2016 Cancer Prevention Pharmaceuticals completes enrolment in its phase III trial for Familial adenomatous polyposis in USA, Canada, Germany, the Netherlands, Belgium, Spain and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top